Intravesical Gemcitabine for Treatment of Superficial Bladder Cancer not Responding to Bacillus Calmette-Guerin Vaccine
Afr. j. urol. (Online)
; 16(4): 110-116, 2010.
Article
in English
| AIM
| ID: biblio-1258095
Responsible library:
CG1.1
RESUMO
Objectives:
Intravesical Bacillus Calmette-Guerin (BCG) vaccine is the mainstay of treatment and prophylaxis in superficial bladder cancer (SBC) as it reduces tumor recurrence and disease progression. About one-third of patients do not respond to BCG. The aim of this study was to determine the efficacy of intravesical gemcitabine in patients with BCG-refractory SBC.Methods:
Twenty three patients with SBC; TaG3; T1G2-G3 or carcinoma in situ (CIS); refractory (after at least 2 courses of intravesical BCG) or intolerant to intravesical BCG therapy were included. Two weeks after complete tumor resection; patients received intravesical gemcitabine twice weekly at a dose of 2.000 mg/100 ml normal saline for 6 consecutive weeks. Two months after the last dose; recurrence-free patients underwent cystoscopy; urinary cytology and 6 random bladder biopsies. Thereafter; patients were evaluated by the same measures every 3 months; as long as there was no recurrence. Patients with complete response (negative cytology and random biopsies) at the first follow-up cystoscopy received a similar maintenance dose once weekly for another 6 weeks.Results:
Twenty one patients completed the study 15 males and 6 females with a mean age of 48.1 (38-72) years. The follow-up was 15 months (range 2-19 months). Thirteen (61.9) patients were recurrence-free after a mean of 17 months. Superficial recurrences were detected in 6 (28.6) patients and progression by stage in 2 patients (9.5). During follow-up; 8 patients had tumor recurrences and 2 had progression to a higher stage. The median recurrence-free time was 14.7 months (5-19 months). The drug was well tolerated and side-effects were mild in all patients; except two one had easily controlled hematuria and the other had leucopenia.Conclusion:
In properly selected patients; gemcitabine seems to be a promising option in the management of high-risk BCG-refractory SBC; especially in those who refuse or are unfit for cystectomy. Long-term efficacy and the role of maintenance therapy have to be properly studied
Search on Google
Index:
AIM (Africa)
Main subject:
Urinary Bladder Neoplasms
/
BCG Vaccine
Language:
English
Journal:
Afr. j. urol. (Online)
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS